Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Payables (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Payables for 13 consecutive years, with $9.9 million as the latest value for Q4 2025.

  • Quarterly Payables fell 65.16% to $9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 65.16% year-over-year, with the annual reading at $9.9 million for FY2025, 65.16% down from the prior year.
  • Payables hit $9.9 million in Q4 2025 for Coherus Oncology, down from $24.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $126.7 million in Q3 2021 to a low of $9.9 million in Q4 2025.
  • Historically, Payables has averaged $39.9 million across 5 years, with a median of $28.9 million in 2023.
  • Biggest five-year swings in Payables: surged 956.59% in 2021 and later crashed 92.17% in 2022.
  • Year by year, Payables stood at $16.2 million in 2021, then dropped by 28.67% to $11.5 million in 2022, then soared by 205.56% to $35.2 million in 2023, then decreased by 19.2% to $28.5 million in 2024, then crashed by 65.16% to $9.9 million in 2025.
  • Business Quant data shows Payables for CHRS at $9.9 million in Q4 2025, $24.9 million in Q3 2025, and $37.6 million in Q2 2025.